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Assessment of commercially available computerized neurocognitive testing in the 




Clinicians frequently use computer-based neurocognitive assessments to aid in the diagnosis and man-
agement of Sport-Related Concussion (SRC). With practitioners using varied Neuro-Cognitive Assess-
ment Tools (NCAT), questions arise concerning differences among NCAT and how these differences 
may affect patient care. The purpose of the current study is to offer a comparative analysis of two 
widely accepted, commercially available computer-based neurocognitive testing modalities in the ado-
lescent concussed athlete. 
Hypothesis  
There will be a difference between the C3 Logix® vs ImPACT® scoring in the IRPT and RTP. 
Study Design 
Retrospective chart review. 
Methods 
In order to identify patients that were diagnosed with SRC, the records of patients reporting to a sports 
medicine practice were reviewed for a period of eighteen months. All patients were assessed with ei-
ther the ImPACT® or C3 Logix NCAT®. The date of the injury (DOI), as well as the patient’s symp-
tom level (IVAL), time to initiation of the return to play protocol (IRTP), and time to the return to play 
(RTP), were recorded. 
Results 
Two hundred and twenty-two records (222) were identified. There was no difference in the symptom 
score (P = 0.22) at the IEVAL between C3 Logix® (31.5±27.0) and ImPACT® (23.2±21.9), in the 
IRTP (P = 0.22) between the C3 Logix® (6.2±4.3 days) and ImPACT® (5.1±4.3 days) or RTP (P = 
0.46) between C3 Logix (12.1±4.9 days) and ImPACT (15.6±19.8 days). Weak to moderate correla-
tions were found between symptom scores, IRTP, and RTP. 
Conclusions 
Clinicians made similar recommendations, independent of the NCAT used, as when to initiate the re-
turn to play protocol and when the patient could ultimately return to play. 
Clinical Relevance 
The particular NCAT utilized by the clinician was not a primary factor in the clinical judgment to-
wards the management of the patient with SRC. 
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Introduction   
 
The incidence of sport-related concussion (SRC) is a growing problem in the field of sports medicine. 
Zhang et al.1  demonstrated that the incidence of concussion in the US population is increasing, 
particularly in adolescent populations. The assessment and management of patients following a head 
injury can be difficult. There is ongoing research within the healthcare community for the optimal 
assessment and treatment protocol for these patients. Standard practices are evolving, and consensus 
documents attempt to suggest “best evidence” standards for the patient with SRC.2,3 Neurocognitive 
Assessment Testing (NCAT) is a validated objective diagnostic and prognostication tool.4 NCATs are 
used by healthcare providers in the clinic setting, as well as in athletic training rooms to assist the 
management of patients with concussion.  
 
Computer-based testing is now commonly used in tandem with symptom scoring tools.5 There are 
several commercially available NCAT products competing to capture shares of a burgeoning market. It 
is unclear which product is superior with an increasing number of NCATs available. There is 
insufficient evidence to establish benefit in using a specific NCAT product for the evaluation, 
management, or monitoring of patients with SRC. There appears to be no clear clinical practice 
standard for the use of NCATs outside of manufacturer guidelines. Practitioner preference and 
familiarity with an NCAT product leads to varying practices among healthcare providers. 
 
NCATs offer several potential advantages over the archetypal paper neuropsychological tests, such as 
the Sport Concussion Assessment Tool (SCAT5), in the assessment of patients with SRC. The ability 
of NCAT’s to diagnose, rule out, and monitor recovery from SRC is unclear as many external factors 
can influence the utility of NCATs. There is a lack of evidence to support the reliability, validity, or 
clinical utility of NCATs. The literature provides some support for the convergent validity of NCAT 
tests.6,7 The results of reliability studies are variable.4 It has been shown that a score on an NCAT 
which indicates a good cognitive function is useful in identifying patients without concussion.8 
However, the utility of an NCAT to rule out SRC is not well documented.9,10 There have been concerns 
raised about the validity of these tests outside the acute 48-hour time frame. It is generally agreed that 
NCATs should not be used in isolation to diagnose or to guide the management of SRC until there is 
more evidence supporting the reliability and validity of NCATs. 
 
The purpose of this retrospective cohort study is to characterize important translational metrics in 
athletic patients affected by sport-related concussion. The investigation determined differences in the 
time to the initiation of a return to play protocol (IRTP), the time to return to play (RTP), the level of 
impairment and concussion symptoms at the initial assessment, at the IRTP and the RTP when the 
clinician was assisted by either the ImPACT® or C3Logix® NCAT. The investigation tested two 
hypotheses. First, there would be a difference between the C3 Logix® vs. ImPACT® scoring in the 
IRPT and RTP, and second, isolated NCAT symptom scores alone are not indicative of RTP; the 












Patients in the current study were entered into the study from patients treated by two sports medicine 
clinics from fall 2015 to spring 2017. A search of the practices’ electronic medical record (Allscripts 
EHR System, Allscripts Healthcare Solutions, Chicago, IL, and EPIC Electronic Medical record) was 
conducted during November 2017. All records were identified with the diagnosis code of S06.0X0 
(concussion without loss of consciousness), S06.0X9 (concussion with loss of consciousness of 
unspecified duration), or S06.0X1 (concussion with loss of consciousness less than 30 minutes). 
Patient records were included if the patient was 13-18 years of age, participated in an interscholastic 
athletic program, and had a diagnosis of an SRC. The project was approved by the University Internal 
Review Board (IRBNet ID# 627321-3). The current study was a retrospective review of records 





Patients included in this study participated in the Sports Medicine Clinic’s baseline concussion testing 
program. Upon presentation, the treating physician performed a post-injury neurocognitive assessment 
and then managed the patient as is customary and usual to their practice.  All patients were evaluated 
on their initial visit to the clinic with either the IMPACT® or C3Logix® NCAT modality, depending 
on the preference of the treating physician. ImPACT® computerized testing is a widely accepted, well-
marketed platform. There is a growing amount of research supporting its utilization in an athletic 
medical setting.11 ImPACT® testing includes tests of verbal and visual memory, reaction time, 
symptom score, visual-motor speed, and impulse control. C3Logix® is a different platform developed 
by the Cleveland Clinic, has similar testing batteries, but also includes other metrics such as a 
vestibular baseline component.12 Repeat testing occurred as deemed necessary by the treating 




The records for all identified patients were reviewed by a single research assistant in order to identify 
the study’s test variables. Patient identifying information was not extracted from the patient records. A 
second investigator reviewed the extracted data for accuracy before data analysis. The investigator 
identified the patient demographic information, the initial date of injury, date of the initial evaluation, 
the date of subsequent evaluations, the results of all clinical tests, NCAT results, date of the initiation 
of the return to play protocol, and the date of return to play. All data were entered into a spreadsheet 




Means and standard deviations for all study variables were calculated. All dependent variables 
followed a normal distribution determined by the Shapiro-Wilk test. The variance of dependent 
variables differed between groups, so Welch’s t-tests were performed to determine between-group 
differences in symptom severity, duration of symptoms, time to the initiation of the return to play 
protocol, and time to return to play. Correlation analysis was used to test the relationship between 
symptom severity, the time to return to play protocol, and the time to return to play. Correlation 
coefficients r = 0 – 0.25 were considered of no correlation, r = 0.26 – 0.50 weak correlation, 0.51 – 
0.75 moderate correlation, and r > 0.75 strong correlation. Multiple regression analysis was used to 
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determine if the initial symptom score of reaction time predicted either the time to initiation of the 
return to play protocol or the time to return to play. Statistical analysis was performed with SPSS 24.0 




Two hundred twenty-two records (222) were entered into the study; five (5) records were missing 
either the date of injury or the date of the initial evaluation and were excluded from the investigation. 
Two hundred seventeen (217) records were entered into the analysis. One hundred ninety-two (192) 
records were evaluated using the ImPACT® testing, and twenty-five (25) were evaluated using the C3 
Logix® system at the time of the initial evaluation. No patients included in the study received more 
than one recorded concussion during the data collection period. The mean time between the date of 
injury (DOI) and the initial evaluation (IEVAL), initiating the return to play protocol (IRPT) and the 
patients' return to play (RPT) can be found in Table 1. There was not a difference (t = -1.226, P = 0.22) 
in the time between the DOI and the IEVAL, IRTP or the RTP between patients evaluated using C3 
Logix® and ImPACT®. The mean symptom score (Table 2) across both devices decreased during the 
time between IEVAL and RTP. Reaction time decreased between IEVAL and RTP (Table 3). The mean 
reaction time across both devices at the IEVAL was 0.743 ± 0.016 sec (n = 155). The mean reaction 
time across both devices at the RTP was 0.619 ± 0.11 sec (n = 95).  
 
Table 1. Time (days) between the injury and the initial evaluation (IEVAL), the initiation of the return to play protocol 






Table 2. Symptom score at the initial evaluation (IEVAL), the initiation of the return to play protocol (IRTP) and return to 







Table 3. Reaction time (seconds) at the initial evaluation (IEVAL), the initiation of the return to play protocol (IRTP) and 







Weak to moderate correlations (Table 4) were found between symptom scores, reaction time, IRTP, 
and RTP. The time between the DOI and IEVAL did not correlate with symptom scores or reaction 
time. The strongest correlation (r = 0.551, P = 0.01) was found between the time to IRTP and RTP. The 
symptom score at the IRTP had a weak correlation (r = 0.464, P < 0.001) to the IEVAL symptom score. 
The reaction time and the symptom score at the IEVAL had a moderate correlation (r = 0.353, P < 
0.001). Multiple regression analysis revealed that the symptom score at the IEVAL predicted the IRPT 
 Mean C3 Logix® ImPACT® T value P-value 
IEVAL 5.2 ± 4.2 6.2 ± 4.3 (n=25) 5.1 ± 4.3 (n=192) -1.229 0.228 
IRTP 15.1 ± 18.4 12.1 ± 4.9 (n=19) 15.6 ± 19.8 (n=110) 1.544 0.125 
RTP 21.5 ± 24.9 18.5 ± 0.5 (n=2) 21.7 ± 4.5 (n=32) 0..697 0.491 
 Mean C3 Logix® ImPACT® T value P-value 
IEVAL 23.9 ± 22.3 31.5 ± 27.0 (n=12) 23.2 ± 21.9 (n=132) -1.033 0.321 
IRTP 6.1 ± 13.3 6.8 ± 18.7 (n=18) 5.9 ± 12.5 (n=137) -0.202 0.842 
RTP 2.2 ± 6.1 0.750 ± 0.018 (n=11) 2.4 ± 6.5 (n=144) 1.192 0.239 
 Mean C3 Logix® ImPACT® T value P-value 
IEVAL 0.743 ± 0.016 0.652 ± 0.081 (n=11) 0.750 ± 0.214 (n=144) 3.243 0.004 
IRTP 0.638 ± 0.11 0.623 ± 0.115 (n=18) 0.639 ± 0.112 (n=132) 0.566 0.577 
RTP 0.619 ± 0.11 0.593 ± 0.123 (n=12) 0.623 ± 0.106 (n=83) 0.802 0.436 
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(r2 = 0.214, P < 0.001), reaction time factor but did not affect the regression model (P = 0.959) while 
the regression equation did not predict the RTP (r2 = 0.010, P = 0.91). 
 





















Discussion   
 
The purpose of the current study was to compare two popular and commercially used neurocognitive 
testing modalities in adolescent concussed athletes. Graham et al8 advocate for increased reliance on 
subjective means for the clinician to employ in their diagnoses and management of concussion 
injuries. Higgins et al13 and Simon et14 al identified ImPACT® and C3 Logix® as a valid means for 
testing symptom scores, respectively. Our results indicate the NCATs tested (C3 Logix® and 
ImPACT®) did not show a difference in their prediction of IRPT based upon symptom score alone. 
Two hundred seventeen (217) records were entered into the study for analysis, with one hundred 
ninety-two (192) evaluated using ImPACT® testing, and twenty-five (25) using C3 Logix® testing. 
The two groups had a similar level of concussion symptoms at the initial evaluation. The mean time 
between IEVAL and initiation if IRTP protocol was 15 ± 18 days.  The considerable deviations to this 
value are likely attributed to the variability in the level of symptom severity and clinician care based 
upon other subjective or objective criteria, such as individual medical history or presenting symptoms 
not captured by tested NCAT criteria. There was not a difference in the time between the DOI and RTP 
between patients evaluated with C3 Logix® (12.1 ± 4.9 days) and ImPACT® (15.6 ± 19.8 days). This 
suggests there is not a major difference in the predictive nature of the NCAT testing modalities studied, 
which is counter to the hypothesis at the onset of the study.  
 
Individuals that had an IRTP greater-than 12 days tended to have a greater symptom score at 
presentation, and individuals that had an IRTP less-than 12 days tended to have a lesser symptom score 
at presentation with C3 Logix® testing. Individuals that had an IRTP greater-than 15 days tended to 
have a greater symptom score at presentation, and individuals that had an IRTP less-than 15 days 
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tended to have a lesser symptom score at presentation with ImPACT® testing. Regression analysis 
revealed that the symptom score at the IEVAL predicted the IRTP (r2 = 0.21, p < 0.001) but not the 
RTP (r2 = 0.01, p = 0.91). This is consistent with known research that symptom score is indicative of 
IRTP.15 However, the low R2 value indicates that still most of the influence comes from other factors 
that are involved in the managing and rehabilitation for concussion injuries.  
 
Mean symptom scores decreased during the time between IEVAL and RTP for both C3 Logix® and 
ImPACT® testing. There was no difference observed in the symptom scores at IEVAL between C3 
Logix® and ImPACT®. For patients participating in the study, neither data set was more severely 
injured based upon presenting symptom score, and the pathology of injury recovery progressed equally 
for both testing modalities. Patients in the study followed a standardized recovery protocol derived 
from the Berlin consensus guidelines.2 
 
The results of the current study must be reviewed in light of the following limitations. The study was 
limited by the disproportionate number tested using the two NCAT testing modalities, with a larger 
patient population tested with ImPACT® (n = 192) than C3 Logix® (n = 25). There was not a 
statistical difference in the symptom scores between the two devices. Due to the disproportioned 
sample sizes, the current study did not attempt to establish equivalence between the measures made 
using the two devices. The purpose of the investigation was to explore if differences between the two 
devices could be found not if the two devices are equivalent. The range of the scores was the same 
between the two devices. Five records were excluded due to incomplete data reducing the sample size 
to 217. Patients were evaluated and managed by five physicians with varying training. However, all 
were experienced in the treatment of concussed athletes. The largest number of patients were managed 
by a single investigator. The finding of long reaction time at IEVAL for patients evaluated with 
ImPACT® must be interpreted with caution. The two tests do not measure reaction time using the 
same criteria and this is likely a spurious finding. All of the clinicians managed their patients using the 
best available clinical evidence. Lastly, there was no attempt to control for concussion history or other 
comorbidities. It is likely concussion history and comorbidities occurred at equal rates in patients 
tested with both NCATs.  
 
Zhang, et al1 identified a rise in the incidence of concussion in the adolescent athletic population; the 
increase in the number of concussive injuries calls for an increase in the understanding of how to 
diagnose and manage these patients. Further research connecting the increasingly widespread use of 
NCATs in both the office and sideline environment may be beneficial to identify a potential correlation 
between these two values. Our data agree with previous literature on the application of NCATs in the 
diagnosis and management of concussion injuries.   
 
The relatively large deviation in IRTP and RTP for both testing devices is most likely attributed to the 
individualized patient care provided by clinicians, which concurs with Johnson et al.5 and the 
suggestion that NCATs can provide clinicians a valid objective means to provide direct care to treat 
targeted deficiencies in neurocognitive function, such as balance or visual acuity insufficiencies. Dessy 
et al11  identified that no single test is sufficient for the stand-alone diagnoses of sports-related 
concussions. Arrieux et al4 have identified there are still questions to the use of NCATs for an accurate 
diagnosis of concussion injuries. Our results expand upon these issues, indicating that two of the most 
common NCAT yield similar results; however, the largest influence remains in the tailored patient care 
provided by the clinician.  
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Research suggests as high as fifty-percent of concussions may go unreported16, which may pose 
challenges for healthcare providers. Further research and advocacy on the increasing use of NCATs 
may propose an actionable solution to decrease the number of unreported concussions. Additional 
research into the development of a specialized protocol for NCAT derived symptom scores, utilizing a 
variety of modalities, may be beneficial in the treatment of future patients. This may serve to provide 
screening tools that can assist the clinical judgment of healthcare providers. There may be 
circumstances that clinicians determine to remove an athlete from play and enter concussion protocol 
based upon other subjective or objective criteria when NCAT scores fall below the concussion 
threshold. Further research into the prevalence of this scenario may prove beneficial to understand the 
role NCATs play in the initial diagnoses of SRC injuries and their function as a means to measure 
recovery from the injury and provide recommendations for the return to play.  
 
The current study focused on the quality and comparison of two widely used NCAT devices in their 
application to the concussed athlete as a means to predict a return to play. It did not focus on major 
differences between the two testing protocols and procedures directed by the respective companies. 
Our results indicated that NCATs provide a minority of predictive means for athlete return to play from 
the initial injury and showed two of the most widely used devices did not display a major difference in 
this area. Presenting symptom score alone was not sufficient to predict IRTP; however, it remained the 
most weighted testing measure across testing devices. The results of this study concur with established 
literature that the most important aspect to the individualized care of the concussed athlete remains the 
expertise and patient knowledge possessed by the managing clinician. 
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